Cargando…
A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A
Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024794/ https://www.ncbi.nlm.nih.gov/pubmed/35456157 http://dx.doi.org/10.3390/pathogens11040482 |
_version_ | 1784690694571425792 |
---|---|
author | Mitteregger, Dieter Wessely, Julian Barišić, Ivan Bedenić, Branka Kosak, Dieter Kundi, Michael |
author_facet | Mitteregger, Dieter Wessely, Julian Barišić, Ivan Bedenić, Branka Kosak, Dieter Kundi, Michael |
author_sort | Mitteregger, Dieter |
collection | PubMed |
description | Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active against meropenem and imipenem. If PCR methods are not the first choice, phenotypic methods have to be implemented. While promising, the carbapenemase inactivation method (CIM) using meropenem-hydrolysis is, however, hampered by poor performance or overly long time-to-result. We developed a rapid CIM (rCIM-A) with good performance using ertapenem, imipenem, and meropenem disks, 2-h permeabilization and incubation with the test strain in trypticase soy broth, and a read-out of residual carbapenem activity after 6 h, and optionally after 16–18 h. Using clinical isolates and type-strains of Acinetobacter (n = 67) not harboring carbapenemases (n = 28) or harboring acquired carbapenemases (n = 39), the sensitivity of detection was 97.4% with the imipenem disk after 6 h at a specificity of 92.9%. If the inhibition zone around the ertapenem disk at 6 h was 6 or ≤26 mm at 16–18 h, or ≤25.5 mm for meropenem, the specificity was 100%. Because of the high negative predictive value, the rCIM-A seems particularly appropriate in areas of lower CRAB-frequency. |
format | Online Article Text |
id | pubmed-9024794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90247942022-04-23 A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A Mitteregger, Dieter Wessely, Julian Barišić, Ivan Bedenić, Branka Kosak, Dieter Kundi, Michael Pathogens Article Carbapenem-resistant Acinetobacter baumannii group organisms (CRAB) are challenging because the choice between targeted, new antibiotic drug options and hygiene measures should be guided by a timely identification of resistance mechanisms. In CRAB, acquired class-D carbapenemases (CHDLs) are active against meropenem and imipenem. If PCR methods are not the first choice, phenotypic methods have to be implemented. While promising, the carbapenemase inactivation method (CIM) using meropenem-hydrolysis is, however, hampered by poor performance or overly long time-to-result. We developed a rapid CIM (rCIM-A) with good performance using ertapenem, imipenem, and meropenem disks, 2-h permeabilization and incubation with the test strain in trypticase soy broth, and a read-out of residual carbapenem activity after 6 h, and optionally after 16–18 h. Using clinical isolates and type-strains of Acinetobacter (n = 67) not harboring carbapenemases (n = 28) or harboring acquired carbapenemases (n = 39), the sensitivity of detection was 97.4% with the imipenem disk after 6 h at a specificity of 92.9%. If the inhibition zone around the ertapenem disk at 6 h was 6 or ≤26 mm at 16–18 h, or ≤25.5 mm for meropenem, the specificity was 100%. Because of the high negative predictive value, the rCIM-A seems particularly appropriate in areas of lower CRAB-frequency. MDPI 2022-04-18 /pmc/articles/PMC9024794/ /pubmed/35456157 http://dx.doi.org/10.3390/pathogens11040482 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mitteregger, Dieter Wessely, Julian Barišić, Ivan Bedenić, Branka Kosak, Dieter Kundi, Michael A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title | A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title_full | A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title_fullStr | A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title_full_unstemmed | A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title_short | A Variant Carbapenem Inactivation Method (CIM) for Acinetobacter baumannii Group with Shortened Time-to-Result: rCIM-A |
title_sort | variant carbapenem inactivation method (cim) for acinetobacter baumannii group with shortened time-to-result: rcim-a |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024794/ https://www.ncbi.nlm.nih.gov/pubmed/35456157 http://dx.doi.org/10.3390/pathogens11040482 |
work_keys_str_mv | AT mittereggerdieter avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT wesselyjulian avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT barisicivan avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT bedenicbranka avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT kosakdieter avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT kundimichael avariantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT mittereggerdieter variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT wesselyjulian variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT barisicivan variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT bedenicbranka variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT kosakdieter variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima AT kundimichael variantcarbapeneminactivationmethodcimforacinetobacterbaumanniigroupwithshortenedtimetoresultrcima |